Cardiovascular Treatment Guidelines

Introduction to Icosapent Ethyl

Icosapent ethyl is a medication used for cardiovascular risk reduction, with proven benefits in patients with established cardiovascular disease or diabetes with additional risk factors, as recommended by the American College of Cardiology and American Heart Association 1, 2, 3, 4 and the American Diabetes Association 5

The American College of Cardiology and American Heart Association recommend icosapent ethyl for patients with established cardiovascular disease or diabetes with additional risk factors who have triglycerides >150 mg/dL while on statin therapy, with a Class 2a recommendation (Level of Evidence: B-R) 1, 2, 3, 4
Patients with controlled LDL-C levels and triglyceride levels >150 mg/dL while on statin therapy may benefit from icosapent ethyl, as shown in the REDUCE-IT trial 5, 6, 2, 3, 4
Patients with diabetes showed similar benefits with icosapent ethyl therapy, with 40% of trial participants having diabetes 2
Patients should be on moderate- or high-intensity statin therapy to be considered for icosapent ethyl for cardiovascular risk reduction, with exclusion criteria including history of pancreatitis, atrial fibrillation, or severe heart failure 3

The recommended dosage of icosapent ethyl is 2 g twice daily with food, for a total daily dose of 4 g/day, with a composition of ≥96% EPA ethyl ester and no DHA 2, 3, 4
The European Society of Cardiology (ESC) guidelines note that very high doses of icosapent ethyl (two times 2 g daily) were used in the REDUCE-IT trial, which showed significant cardiovascular benefit 7

Icosapent ethyl demonstrated significant cardiovascular risk reduction in the REDUCE-IT trial, with a 26% reduction in the composite of cardiovascular death, nonfatal MI, or nonfatal stroke 6, 5, 2
Icosapent ethyl reduces cardiovascular events by 25% in patients with established cardiovascular disease or diabetes with at least two additional cardiovascular risk factors who have triglyceride levels >150 mg/dL while on statin therapy, as recommended by the American Diabetes Association 5
Icosapent ethyl is superior to saroglitazar for cardiovascular risk reduction, with proven cardiovascular outcome benefits, whereas saroglitazar lacks long-term cardiovascular outcome data 6

Icosapent ethyl is generally well-tolerated with a safety profile similar to placebo, but with notable adverse effects including increased risk of atrial fibrillation (5.3% vs. 3.9% with placebo) and atrial fibrillation requiring hospitalization (3.1% vs. 2.1%) 6
Patients taking icosapent ethyl should be monitored for atrial fibrillation symptoms, bleeding events, especially in patients taking anticoagulants or antiplatelet therapies 6, 4
Lipid levels should be monitored to assess treatment efficacy with icosapent ethyl, with maximum effects typically occurring after 4-12 weeks 3, 8, 4
Icosapent ethyl does not increase LDL-C levels, which is an advantage over some other triglyceride-lowering therapies 4